PLUS1
Best deals to access real time data! |
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type | ISIN |
|---|---|---|---|---|
| Cytodyn Inc. (QB) | CYDY | Other OTC | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.0075 | -1.47% | 0.5025 | 0.515 | 0.499355 | 0.5 | 0.51 | 16:00:01 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.481 | 0.505 | 0.024 | 4.75% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 104 | 286,698 | $ 0.5051 | $ 144.81k | 439.43k | 0.06 - 0.71 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:53:19 | 500 | $0.50 | USD |
Cytodyn Inc. (QB) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 153.02M | 304.52M | $ -50.15M | - | -3.05 | 241.41M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Cytodyn Inc. (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/25/2019 | 16:24 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 2/22/2019 | 16:03 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/20/2019 | 17:30 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/15/2019 | 05:03 | Edgar (US Regulatory) | Notice of Effectiveness (effect) |
| 2/14/2019 | 08:33 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) |
| 2/13/2019 | 11:48 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3/a) |
| 2/13/2019 | 06:32 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 0 | 0.515 | 0 | 0.0000 | 0 | 287k | 0 | - | - |
| 1 Month | 0 | 0.515 | 0 | 0.0000 | 0 | 287k | 0 | - | - |
| 3 Months | 0 | 0.515 | 0 | 0.0000 | 0 | 287k | 0 | - | - |
| 6 Months | 0 | 0.515 | 0 | 0.0000 | 0 | 287k | 0 | - | - |
| 1 Year | 0 | 0.515 | 0 | 0.0000 | 0 | 287k | 0 | - | - |
| 3 Years | 0 | 0.515 | 0 | 0.0000 | 0 | 287k | 0 | - | - |
| 5 Years | 0 | 0.515 | 0 | 0.0000 | 0 | 287k | 0 | - | - |
Cytodyn Inc. (QB) Description
| CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn's lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments. |
